Glutathione: A Promising Therapy for Parkinson’s Disease
By Devin Wilson, NMD
Glutathione (GSH), a naturally occurring antioxidant, is crucial for protecting cells from damage, detoxifying toxins, and supporting the general health and longevity of cells. Likely due to its antioxidant and detoxification properties Glutathione is critically important in Parkinson’s Disease.
Low glutathione levels may play a major role in causing the disease
Over 30 years have past since the first data was published that showed people with Parkinson’s disease have a 40-50% deficit in total glutathione levels. Reduced levels of glutathione is considered one of the earliest biochemical changes to occur in Parkinson’s and recent evidence suggests it plays a major role in causing the disease.
“All patients improved significantly after GSH therapy, with a 42% decline in disability.”
Multiple scientific articles and studies have been published including two clinical trials of IV glutathione. The first in 1996, which showed improvements in motor symptoms and improvement in disability which lasted 2-4 months after finishing the treatment. “All patients improved significantly after GSH therapy, with a 42% decline in disability.” Their data indicates that “that in untreated PD patients, GSH has symptomatic efficacy and possibly retards the progression of the disease.”
In 2009, another study showed that IV Glutathione was overall safe, well tolerated and demonstrated benefits in some Parkinson’s symptoms.
glutathione is a promising therapy for Parkinson’s
More recently, the Michael J. Fox Foundation, which is dedicated to finding a cure for Parkinson's disease through aggressively funded research. funded a Phase IIb. The study investigated the use of intranasal glutathione in Parkinson’s Disease. Although their results did not suggest that intranasal glutathione was better than placebo, they conclude that glutathione is a promising therapy for Parkinson’s and recognize the urgent need for therapies that improve symptoms and modify disease.
The video below is from David Perlmutter, MD and demonstrates the potential impact intravenous glutathione can have on patients with Parkinson’s Disease. Dr. Perlmutter is a Board-Certified Neurologist and six-time New York Times bestselling author. He serves on the Board of Directors and is a Fellow of the American College of Nutrition.
***Caution, this video may cause tears of hope and joy***
https://www.youtube.com/watch?v=fDkkzILyZwM
Valley Integrative Health offers comprehensive treatment of Parkinson’s Disease. In addition to using conventional treatments, Devin Wilson, NMD uses evidenced based therapies that have been shown to be effective. He has compiled scientific data, clinical studies and published protocols along with over 10 years of clinical experience into a therapeutic model to support individuals with Parkinson’s Disease.
Valley Integrative Health offers early screening, thorough assessment and comprehensive evidence based treatment of Parkinson’s Disease.
Learn more at www.VIHclinic.com
https://pubmed.ncbi.nlm.nih.gov/19542204/
https://pubmed.ncbi.nlm.nih.gov/8938817/
https://pubmed.ncbi.nlm.nih.gov/19230029/
https://www.michaeljfox.org/grant/phase-iib-study-intranasal-glutathione-parkinsons-disease